Sign Out
Tablet: Effects on Ability to Drive and Use Machines: They have been no studies to investigate the effect of Acyclovir on driving performance or the ability to operate machinery. Further, a detrimental effect on such activities cannot be predicted from the pharmacology of the active substance.
Mutagenicity: The results of a wide range of mutagenicity test in vitro and in vivo indicates that acyclovir does not pose a genetic risk to man.
In severely immune-compromized patients (e.g. AIDS patients or bone marrow transplant recipients), oral acyclovir should be considered. Such patients should be encouraged to consult a physician concerning the treatment of any infection.
Cream: The recommended dosage, frequency of applications, and length of treatment should not be exceeded.
Acylete Cream is not recommended for application to mucous membranes, such as in the mouth, eye or vagina. Particular care should be taken to avoid accidental introduction into the eye.
In severely immune compromised patients (e.g. AIDS patients or bone marrow transplant recipients), oral acyclovir should be considered. Such patients should be encouraged to consult a physician concerning the treatment of any infection.
Teratogenic Effects: Acyclovir was not teratogenic in mouse, rabbit or in standard tests in the rat. There are no adequate and well-controlled studies in pregnant women. Acyclovir should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.
Carcinogenesis, Mutagenesis, Impairment of Fertility: No chromosome damage was observed at maximum tolerated parenteral doses of 100 mg/kg acyclovir in rats or chinese hamsters. No evidence of mutagenicity was observed in mammalin cell. Acyclovir does not impair fertility or reproduction in mice at subcutaneous doses up to 25 mg/kg/day.
Use in Lactation: It is not known whether topically applied acyclovir is excreted in breast milk. Caution should be exercised when Acyclovir cream is administered to a nursing woman.
